{"schema_version":"secwatch.filing_event.v1","accession":"0000009326-26-000016","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.949540+00:00","generated_at":"2026-05-15T01:29:06.980747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)","bullets":["Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.","Adjusted EBITDA $74.3M (+12.1%); free cash flow $33.8M; operating cash flow $40.1M.","All three segments posted sales and earnings growth; record Q1 net sales, EBITDA, and net earnings.","New clinical fMRI study on VitaCholine suggests cognitive health benefits in post-menopausal women.","CEO cites strong business model resilience; no guidance change despite geopolitical and trade uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0000009326-26-000016","json":"https://secwatch.observer/filing/0000009326-26-000016.json","markdown":"https://secwatch.observer/filing/0000009326-26-000016.md","text":"https://secwatch.observer/filing/0000009326-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000000932626000016/0000009326-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000000932626000016/bcpc-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:29:06.980747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ffab3ea026d08c355c6964f313966bcd451bfc5","claim":"BALCHEM CORP reported first quarter ended March 31, 2026 results: revenue $270.7 million, net income $40.3 million, EPS $1.25 per diluted share.","evidence_excerpt":"First Quarter 2026 Financial Highlights: • Net sales were $270.7 million, an increase of 8.1% compared to the prior year quarter. • GAAP net earnings were $40.3 million, an increase of 8.7% from the prior year quarter. • Adjusted EBITDA was $74.3 million, an increase of 12.1% from the prior year quarter. • GAAP earnings per share was $1.25 compared to $1.13 in the prior year quarter and adjusted earnings per share (a) was $1.33 compared to $1.22 in the prior year quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/9326/000000932626000016/0000009326-26-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$270.7 million"},{"label":"Net income","value":"$40.3 million"},{"label":"EPS","value":"$1.25 per diluted share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}